Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran (H.G.), Infectious and Tropical Diseases Research Center, (M.S.), Department of Medical Nanotechnology, School of Advanced Medical Sciences,Tabriz University of Medical Sciences, Tabriz, Iran (A.Z.), Department of Biological Science, Kharazmi University, Tehran, Iran (Z.S.), Department of Medical Biotechnology, Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran (F.R.), Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran (Z.B.), Cellular and Molecular Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran (S.Sar), Cellular and Molecular Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran (R.S.), Finetech in Medicine Research Center, Iran University of Medical Sciences, Tehran, Iran (S.Sh), Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran (O.S), Cellular and Molecular Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran (S.Sha), Material Engineering Department, College of Science Koç University, Istanbul 34450, Turkey (Z.N.), Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran (R.Sh).
Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran (H.G.), Infectious and Tropical Diseases Research Center, (M.S.), Department of Medical Nanotechnology, School of Advanced Medical Sciences,Tabriz University of Medical Sciences, Tabriz, Iran (A.Z.), Department of Biological Science, Kharazmi University, Tehran, Iran (Z.S.), Department of Medical Biotechnology, Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran (F.R.), Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran (Z.B.), Cellular and Molecular Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran (S.Sar), Cellular and Molecular Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran (R.S.), Finetech in Medicine Research Center, Iran University of Medical Sciences, Tehran, Iran (S.Sh), Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran (O.S), Cellular and Molecular Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran (S.Sha), Material Engineering Department, College of Science Koç University, Istanbul 34450, Turkey (Z.N.), Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran (R.Sh)
Mol Pharmacol. 2021 Aug;100(2):119-143. doi: 10.1124/molpharm.121.000234. Epub 2021 May 14.
Most commonly recognized as a catabolic pathway, autophagy is a perplexing mechanism through which a living cell can free itself of excess cytoplasmic components, i.e., organelles, by means of certain membranous vesicles or lysosomes filled with degrading enzymes. Upon exposure to external insult or internal stimuli, the cell might opt to activate such a pathway, through which it can gain control over the maintenance of intracellular components and thus sustain homeostasis by intercepting the formation of unnecessary structures or eliminating the already present dysfunctional or inutile organelles. Despite such appropriateness, autophagy might also be considered a frailty for the cell, as it has been said to have a rather complicated role in tumorigenesis. A merit in the early stages of tumor formation, autophagy appears to be salutary because of its tumor-suppressing effects. In fact, several investigations on tumorigenesis have reported diminished levels of autophagic activity in tumor cells, which might result in transition to malignancy. On the contrary, autophagy has been suggested to be a seemingly favorable mechanism to progressed malignancies, as it contributes to survival of such cells. Based on the recent literature, this mechanism might also be activated upon the entry of engineered nanomaterials inside a cell, supposedly protecting the host from foreign materials. Accordingly, there is a good chance that therapeutic interventions for modulating autophagy in malignant cells using nanoparticles may sensitize cancerous cells to certain treatment modalities, e.g., radiotherapy. In this review, we will discuss the signaling pathways involved in autophagy and the significance of the mechanism itself in apoptosis and tumorigenesis while shedding light on possible alterations in autophagy through engineered nanomaterials and their potential therapeutic applications in cancer. SIGNIFICANCE STATEMENT: Autophagy has been said to have a complicated role in tumorigenesis. In the early stages of tumor formation, autophagy appears to be salutary because of its tumor-suppressing effects. On the contrary, autophagy has been suggested to be a favorable mechanism to progressed malignancies. This mechanism might be affected upon the entry of nanomaterials inside a cell. Accordingly, therapeutic interventions for modulating autophagy using nanoparticles may sensitize cancerous cells to certain therapies.
自噬通常被认为是一种分解代谢途径,是一种复杂的机制,通过该机制,活细胞可以通过特定的膜泡或充满降解酶的溶酶体来清除多余的细胞质成分,即细胞器。当细胞暴露于外部刺激或内部刺激时,它可能会选择激活这种途径,通过这种途径,它可以控制细胞内成分的维持,从而通过拦截不必要结构的形成或消除已经存在的功能失调或无用的细胞器来维持体内平衡。尽管如此,自噬也可能被认为是细胞的一种脆弱性,因为它在肿瘤发生中被认为具有相当复杂的作用。在肿瘤形成的早期阶段,自噬似乎是有益的,因为它具有肿瘤抑制作用。事实上,几项肿瘤发生的研究报告称,肿瘤细胞中的自噬活性降低,这可能导致向恶性肿瘤的转化。相反,自噬被认为是一种有利于进展性恶性肿瘤的机制,因为它有助于这些细胞的存活。基于最近的文献,这种机制也可能在工程纳米材料进入细胞时被激活,据称这可以保护宿主免受外来物质的侵害。因此,使用纳米颗粒调节恶性细胞自噬的治疗干预措施有可能使癌细胞对某些治疗方法(例如放射疗法)敏感。在这篇综述中,我们将讨论自噬涉及的信号通路以及该机制本身在细胞凋亡和肿瘤发生中的重要性,并探讨工程纳米材料对自噬的可能改变及其在癌症中的潜在治疗应用。
意义陈述:自噬在肿瘤发生中被认为具有复杂的作用。在肿瘤形成的早期阶段,自噬似乎是有益的,因为它具有肿瘤抑制作用。相反,自噬被认为是一种有利于进展性恶性肿瘤的机制。这种机制可能会受到纳米材料进入细胞的影响。因此,使用纳米颗粒调节自噬的治疗干预措施可能会使癌细胞对某些疗法敏感。
Curr Cancer Drug Targets. 2011-3
Exp Mol Med. 2012-2-29
Curr Pharm Des. 2010-1
Drug Resist Updat. 2025-1
Free Radic Biol Med. 2012-7-20
Trends Mol Med. 2013-5-25
Mol Cancer Ther. 2011-8-30
Int J Nanomedicine. 2025-6-23
Cancer Rep (Hoboken). 2025-2
Front Oncol. 2023-12-15
J Nanobiotechnology. 2023-8-2
Oncol Rep. 2023-1